Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial ResultsGlobeNewsWire • 08/04/22
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver FibrosisBenzinga • 06/27/22
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL's International Liver Congress™GlobeNewsWire • 06/25/22
Madrigal Pharmaceuticals, Inc. (MDGL) CEO Paul Friedman on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial ResultsGlobeNewsWire • 05/09/22
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial ResultsGlobeNewsWire • 02/24/22
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular HealthGlobeNewsWire • 01/31/22
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31stGlobeNewsWire • 01/30/22
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of ResmetiromGlobeNewsWire • 12/30/21
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor ConferencesGlobeNewsWire • 11/23/21